United Microelectronics, 3D Systems leads the premarket losers' pack
TDH Holdings (PETZ) -9%.Ur-Energy (URG) -10%.GEE Group (JOB) -8%.3D Systems (DDD) -8% after cut to underweight at JPMorgan on valuation.GrafTech International (EAF) -7% after launches secondary offering by existing stockholder.Village Farms International (VFF) -7% after announces 
Seekingalpha · 01/15 13:25
ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort
ASLAN Pharmaceuticals (ASLN) has received approval from the Data Monitoring Committee ((DMC)) to start recruitment of patients into the final expansion cohort in its ongoing randomised, double-blind placebo-controlled multiple ascending
Seekingalpha · 01/11 12:56
ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
\- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels \- Data Monitoring Committee approved proposal to open the expansion cohort based on ...
GlobeNewswire · 01/11 10:34
Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study
Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.
Zacks · 01/08 14:57
Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study · 01/08 14:32
Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans · 01/07 18:01
REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
Zacks · 01/06 16:13
REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program · 01/06 16:07
Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs
Zacks · 01/06 14:24
Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs · 01/06 14:15
AAME, AIH, GDS and VRAY among after-hours movers
Gainers: [[AAME]] +53.3%. [[BPFH]] +27.8%. [[AIH]] +11.4%. [[ASLN]] +11.2%. [[GRTS]] +10.1%.Losers: [[VRAY]] -11.1%. [[GDS]] -8.4%. [[PBYI]] -5.5%. [[ACY]] -5.4%. [[GBIO]] -5.3%.
Seekingalpha · 01/04 22:54
Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress
Zacks · 01/04 14:34
Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress · 01/04 12:55
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU
Zacks · 12/30/2020 16:25
ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Buy: Rationale Behind the Upgrade
ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Zacks · 12/25/2020 17:00
Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer
Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.
Zacks · 12/23/2020 15:06
Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate
Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.
Zacks · 12/22/2020 15:27
ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data
Zacks · 12/22/2020 15:22
Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU
Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.
Zacks · 12/21/2020 15:13
iQIYI, Galapagos leads premarket losers' pack
Concord Medical Services Holdings (CCM) -40%.vTv Therapeutics (VTVT) -33% after azeliragon flunks in mid-stage alzheimer’s and diabetes study.BioLineRx (BLRX) -27% despite promising motixafortide data in pancreatic cancer.NanoVibronix (NAOV) -17%.Galapagos (GLPG) -15% after signing new commercialization pact for
Seekingalpha · 12/16/2020 13:31
Webull provides a variety of real-time ASLN stock news. You can receive the latest news about Aslan Pharms through multiple platforms. This information may help you make smarter investment decisions.
About ASLN
ASLAN Pharmaceuticals Limited (ASLAN) is a clinical-stage immunology and oncology-focused biopharmaceutical company. ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.